- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02673866
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
July 26, 2016 updated by: Daiichi Sankyo, Inc.
A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
The hypothesis of this Phase 2 study is that at least 1 dose regimen of DS-1971a will demonstrate clinical superiority to placebo in managing pain associated with DPNP, and will be generally well tolerated.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥ 18 years of age.
- Body mass index (BMI) ≤ 40 kg/m2 at screening.
- Able to give written informed consent.
- Type 1 or 2 diabetes.
- HbA1c ≥ 7.0% and < 9% at screening.
- On a stable anti-diabetic medication regimen (unchanged dose over the last 3 months for diabetes) prior to screening (insulin therapy is acceptable); no recent (i.e., within the previous 6 months) hospitalizations due to noncompliance or uncontrolled diabetes or introduction of new medications.
- ADPS of ≥ 4 on the 11-point numeric rating scale (NRS) over the past 7 days prior to randomization (based on completion of at least 4 daily pain diaries during the 7-day baseline period prior to randomization).
- Painful distal symmetrical sensorimotor polyneuropathy diagnosed for at least 6 months (positive Douleur Neuropathique 4 [DN4] questionnaire at screening).
- Women of child bearing potential (WOCBP) must be willing to use double-barrier contraception for the entire study.
- Subjects who, in the judgement of the Investigator, are likely to be compliant during the study.
Exclusion Criteria:
- Clinically significant unstable neurologic, psychiatric, ophthalmologic, hepatobiliary, respiratory, or hematologic illness or unstable cardiovascular disease (e.g., severe hypotension, uncontrolled cardiac arrhythmia, or myocardial infarction) or any other concurrent disease within 12 months prior to screening that in the opinion of the Investigator would interfere with study participation or assessment of safety and tolerability.
- Subjects who present with active cancer or human immunodeficiency virus (HIV) infection.
- Creatinine clearance rate < 60 mL/min.
- Current diagnosis of epilepsy or any seizure disorder requiring chronic therapy with anti-epileptics.
- Diagnosis of mononeuropathy.
- Subjects who are at risk of suicide as defined by their responses to the C-SSRS or in the opinion of the Investigator. Note: Subjects answering "yes" to any of the questions about suicidal ideation/intent/behaviors occurring within the past 12 months must be excluded (C-SSRS Suicide Ideation section-Questions 1, 2, 3, 4, or 5; C-SSRS Suicidal Behavior section, any of the suicide behaviors questions). Such subjects should be referred immediately to a mental health professional for appropriate evaluation.
- Any major uncontrolled psychiatric disorders such as bipolar disorder, schizophrenia, or major depression.
- Abnormal liver function (aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 2.5 × upper limit of normal (ULN), bilirubin > 1.5 ULN).
- Subjects with history of gout, and/or urate nephrolithiasis, and/or with abnormally low serum uric acid (below the lowest laboratory reference range both in men and women) at baseline.
- Other sources of pain that may confound assessment or self-evaluation of DPNP such as disseminated osteoarthritis or rheumatoid arthritis.
- Neurologic disorders unrelated to diabetic peripheral neuropathy that may confound the assessment of DPNP.
- Amputation of lower extremity (including above- and below-knee amputation) due to diabetes mellitus.
- Unable or unwilling to discontinue current medications for chronic pain for the duration of the trial.
- Use of concomitant medications (i.e., opioids, tricyclic anti-depressives, and/or gamma retinoids) that may confound assessments of efficacy and/or safety.
- Inability or unwillingness to discontinue any other prohibited concomitant medications (see Section 5.6).
- Abuse or dependence on prescription medications, street drugs, or alcohol within the last year.
- Women who are pregnant or breast-feeding or intend to become pregnant during the study period.
- Known hypersensitivity to pregabalin or DS-1971a and/or known treatment failure on pregabalin.
- Subjects who are a family member of the Investigator or any associate, colleague, and employee assisting in the conduct of the study (secretary, nurse, technician).
- Subjects who cannot be contacted by phone in an emergency.
- Participated in another clinical study within 30 days prior to screening or is receiving other investigational agents.
- Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: DS-1971a 400 mg TID
DS-1971a 400 mg three times per day (TID)
|
|
Experimental: DS1971a 400 mg BID
DS1971a 400 mg twice per day (BID)
|
|
Experimental: DS1971a 100 mg BID
|
|
Active Comparator: Pregabalin
|
pregabalin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in weekly Average Daily Pain Score (ADPS)
Time Frame: week 0 (Baseline) to Week 7
|
week 0 (Baseline) to Week 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate, proportion of subjects with ≥ 30% or ≥ 50% reduction
Time Frame: week 0 (Baseline) to Week 7
|
Response rate, defined as the proportion of subjects with ≥ 30% or ≥ 50% reduction
|
week 0 (Baseline) to Week 7
|
Effect of DS-1971a on Patient Global Impression of Change (PGIC) in neuropathic pain
Time Frame: week 7
|
Effect of DS-1971a on Patient Global Impression of Change (PGIC) in neuropathic pain
|
week 7
|
Effect of DS-1971a on pain intensity and severity
Time Frame: week 7
|
Effect of DS-1971a on pain intensity and severity as assessed by the Short-Form McGill Pain Questionnaire (SF-MPQ)
|
week 7
|
Effect of DS-1971a on pain intensity and severity
Time Frame: week 7
|
Effect of DS-1971a on pain interference with daily activities as assessed by a modified Brief Pain Inventory Short Form (BPI-SF)
|
week 7
|
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: week 0 (Baseline) to Week 7
|
Change as assessed by the Hospital Anxiety and Depression Scale (HADS)
|
week 0 (Baseline) to Week 7
|
Change in pain-associated sleep interference score (ADSIS)
Time Frame: week 0 (Baseline) to Week 7
|
Change in pain-associated sleep interference as assessed by average daily sleep interference score (ADSIS)
|
week 0 (Baseline) to Week 7
|
Changes in subject general health status
Time Frame: week 0 (Baseline) to Week 7
|
Changes in subject general health status as assessed by the Short Form 36 (SF-36) questionnaire
|
week 0 (Baseline) to Week 7
|
number and severity of Adverse Events (AEs), clinical laboratory abnormalities, physical examinations, ECGs, vital signs
Time Frame: week 0 (Baseline) to Week 7
|
number and severity of AEs, clinical laboratory abnormalities, physical examinations, 12-lead electrocardiograms (ECGs), and vital signs
|
week 0 (Baseline) to Week 7
|
change in Columbia-Suicide Severity Rating Scale (C SSRS)
Time Frame: week 0 (Baseline) to Week 7
|
change in Columbia-Suicide Severity Rating Scale (C SSRS)
|
week 0 (Baseline) to Week 7
|
Effects of treatments on neuropathic pain components
Time Frame: week 7
|
Effects of treatments on neuropathic pain components assessed with the Neuropathic Pain Symptom Inventory (NPSI)
|
week 7
|
change in weekly ADPS responder rate
Time Frame: week 7
|
Effects of DS-1971a versus pregabalin (titrated to 300 mg daily) in weekly ADPS responder rate at Week 7
|
week 7
|
Rescue medication usage
Time Frame: week 0 through week 7
|
Rate of rescue medication usage
|
week 0 through week 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Anticipated)
January 1, 2017
Study Completion (Anticipated)
February 1, 2017
Study Registration Dates
First Submitted
January 28, 2016
First Submitted That Met QC Criteria
February 1, 2016
First Posted (Estimate)
February 4, 2016
Study Record Updates
Last Update Posted (Estimate)
July 27, 2016
Last Update Submitted That Met QC Criteria
July 26, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Neuralgia
- Diabetic Neuropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Anti-Anxiety Agents
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Pregabalin
- DS-1971a
Other Study ID Numbers
- DS1971-A-U202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States